Enovis Corporation (NYSE:ENOV) Receives $46.71 Average PT from Analysts

Enovis Corporation (NYSE:ENOV) has received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $46.7143.

A number of research firms recently issued reports on ENOV. BTIG Research initiated coverage on Enovis in a research note on Tuesday, January 6th. They set a “buy” rating and a $41.00 price target on the stock. Canaccord Genuity Group decreased their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. UBS Group reaffirmed a “buy” rating and issued a $50.00 target price on shares of Enovis in a report on Monday, January 5th. Wells Fargo & Company upped their price target on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th.

Enovis Trading Down 1.8%

NYSE ENOV opened at $21.78 on Friday. The firm’s fifty day moving average price is $26.20 and its 200 day moving average price is $28.77. Enovis has a 12 month low of $21.00 and a 12 month high of $47.26. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -0.92 and a beta of 1.52.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. The firm had revenue of $548.91 million during the quarter, compared to analysts’ expectations of $538.61 million. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. Enovis’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.73 earnings per share. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. On average, sell-side analysts expect that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider John Kleckner acquired 2,468 shares of Enovis stock in a transaction on Tuesday, November 25th. The shares were bought at an average cost of $30.32 per share, with a total value of $74,829.76. Following the completion of the purchase, the insider owned 12,302 shares in the company, valued at $372,996.64. The trade was a 25.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 2.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enovis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital Fund Management S.A. purchased a new stake in Enovis during the second quarter worth $1,682,000. Assenagon Asset Management S.A. acquired a new position in shares of Enovis during the 3rd quarter worth $4,045,000. Rhumbline Advisers boosted its position in shares of Enovis by 32.4% in the 2nd quarter. Rhumbline Advisers now owns 172,341 shares of the company’s stock worth $5,405,000 after buying an additional 42,138 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of Enovis by 56.0% in the 2nd quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock worth $4,382,000 after buying an additional 50,156 shares in the last quarter. Finally, Boston Partners grew its stake in Enovis by 42.4% in the 2nd quarter. Boston Partners now owns 1,382,724 shares of the company’s stock valued at $43,352,000 after acquiring an additional 411,744 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.